Short Interest in Apollomics Inc. (NASDAQ:APLM) Drops By 55.8%

Apollomics Inc. (NASDAQ:APLM) saw a large decline in short interest in April. As of April 30th, there was short interest totaling 2,692 shares, a decline of 55.8% from the April 15th total of 6,089 shares. Based on an average daily volume of 4,283 shares, the days-to-cover ratio is presently 0.6 days. Currently, 0.1% of the shares of the company are short sold.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the company. Wall Street Zen raised Apollomics from a “sell” rating to a “hold” rating in a research note on Saturday, January 17th. Weiss Ratings downgraded Apollomics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock has a consensus rating of “Sell”.

Institutional Investors Weigh In On Apollomics

An institutional investor recently bought a new position in Apollomics stock. Kestra Advisory Services LLC purchased a new position in Apollomics Inc. (NASDAQ:APLM) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 4,380 shares of the company’s stock, valued at approximately $82,000. Kestra Advisory Services LLC owned 0.40% of Apollomics at the end of the most recent reporting period. Institutional investors own 19.13% of the company’s stock.

Apollomics Price Performance

APLM stock opened at $14.59 on Friday. The company’s 50-day moving average price is $16.06 and its 200 day moving average price is $17.50. Apollomics has a 52 week low of $3.66 and a 52 week high of $42.12.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company based in Palo Alto, California, focuses on the development of innovative targeted therapies and immuno-oncology agents for the treatment of cancer. The company’s research and development efforts center on small molecule inhibitors and monoclonal antibodies designed to address key pathways involved in tumor growth and immune evasion. Its lead asset, dalpiciclib (formerly SHP654), is a selective oral CDK4/6 inhibitor in Phase III trials for metastatic breast cancer, and Apollomics holds a number of additional early-stage programs targeting solid tumors and hematologic malignancies.

Founded in 2015, Apollomics has established research and clinical collaboration networks across North America, China and Europe.